BRAF and melanoma: This is illustrated in the combination of a BRAF inhibitor dabrafenib with a MEK inhibitor trametinib, which suppresses paradoxical reactivation and resistance observed in patients with BRAF-mutated melanoma treated with dabrafenib alone (Zhong et al., 2022; Banzi et al., 2016).